SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Boston Scientific Corp – ‘8-K’ for 3/9/21

On:  Thursday, 3/11/21, at 4:41pm ET   ·   For:  3/9/21   ·   Accession #:  885725-21-10   ·   File #:  1-11083

Previous ‘8-K’:  ‘8-K’ on / for 3/3/21   ·   Next:  ‘8-K’ on / for 4/28/21   ·   Latest:  ‘8-K’ on 5/13/21 for 5/10/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/11/21  Boston Scientific Corp            8-K:5,9     3/09/21   12:219K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         8-K March 11, 2021                                  HTML     29K 
 8: R1          Cover Document                                      HTML     53K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- bsx-20210309_htm                    XML     30K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.CAL  XBRL Calculations -- bsx-20210309_cal                XML      7K 
 4: EX-101.DEF  XBRL Definitions -- bsx-20210309_def                 XML     41K 
 5: EX-101.LAB  XBRL Labels -- bsx-20210309_lab                      XML     87K 
 6: EX-101.PRE  XBRL Presentations -- bsx-20210309_pre               XML     42K 
 2: EX-101.SCH  XBRL Schema -- bsx-20210309                          XSD     13K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    21K 
12: ZIP         XBRL Zipped Folder -- 0000885725-21-000010-xbrl      Zip     16K 


‘8-K’   —   8-K March 11, 2021


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  bsx-20210309  
 i 0000885725 i false00008857252021-03-092021-03-090000885725us-gaap:CommonStockMember2021-03-092021-03-090000885725bsx:SeniorNotedue2027Member2021-03-092021-03-090000885725bsx:A550MCPSSeriesAMember2021-03-092021-03-09


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________

FORM  i 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________

Date of Report (Date of earliest event reported): March 11, 2021 ( i March 9, 2021)
 i BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)

 i Delaware i 1-11083 i 04-2695240
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

     i 300 Boston Scientific Way,  i Marlborough,  i Massachusetts                  i 01752-1234
    (Address of principal executive offices)                           (Zip Code)

( i 508)  i 683-4000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 i Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
 i Common Stock, $0.01 par value per share i BSX i New York Stock Exchange
 i 0.625% Senior Notes due 2027 i BSX27 i New York Stock Exchange
 i 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share i BSX PR A i New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   



ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On March 9, 2021, Stephen P. MacMillan informed the Company that he will not stand for re-election at the Company’s 2021 Annual Meeting. Mr. MacMillan has served as a member of the Board since April 2015 and currently serves as a member of the Executive Compensation and Human Resources Committee and the Nominating and Governance Committee. Mr. MacMillan will continue to serve as a director and in his committee roles until the 2021 Annual Meeting, to be held on May 6, 2021. Mr. MacMillan’s decision not to stand for re-election at the 2021 Annual Meeting is not the result of any disagreement with the Company.

Following the 2021 Annual Meeting, subject to their reelection by the stockholders, the Board will be composed of nine directors. The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Mr. MacMillan’s departure is in the best interest of the Company.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits

Exhibit No.
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                

Date:March 11, 2021BOSTON SCIENTIFIC CORPORATION
By:/s/ Vance R. Brown
Vance R. Brown
Vice President and Chief Corporate Counsel



Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
5/6/21None on these Dates
Filed on:3/11/21
For Period end:3/9/21
 List all Filings 
Top
Filing Submission 0000885725-21-000010   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 15, 7:42:02.0am ET